{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T11:25:41Z","timestamp":1787225141382,"version":"build-2736575974"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1016\/j.lungcan.2023.03.003","type":"journal-article","created":{"date-parts":[[2023,3,8]],"date-time":"2023-03-08T11:14:03Z","timestamp":1678274043000},"page":"237-246","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["TROP2 expression and SN38 antitumor activity in malignant pleural mesothelioma cells provide a rationale for antibody-drug conjugate therapy"],"prefix":"10.1016","volume":"178","author":[{"given":"Luca","family":"Heged\u00fcs","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00d6zlem","family":"Okumus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabian","family":"Mairinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Till","family":"Ploenes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Reuter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Schuler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anja","family":"Welt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Vega-Rubin-de-Celis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"Theegarten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnes","family":"Bankfalvi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clemens","family":"Aigner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Balazs","family":"Heged\u00fcs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.lungcan.2023.03.003_b0005","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1016\/j.ajpath.2012.12.028","article-title":"New insights into understanding the mechanisms, pathogenesis, and management of malignant mesotheliomas","volume":"182","author":"Mossman","year":"2013","journal-title":"Am J Pathol"},{"issue":"9","key":"10.1016\/j.lungcan.2023.03.003_b0010","doi-asserted-by":"crossref","first-page":"2972","DOI":"10.1080\/21645515.2021.1917933","article-title":"Immune checkpoint inhibitors for unresectable malignant pleural mesothelioma","volume":"17","author":"Metro","year":"2021","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.lungcan.2023.03.003_b0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2019.104398","article-title":"Irinotecan: 25 years of cancer treatment","volume":"148","author":"Bailly","year":"2019","journal-title":"Pharmacol Res"},{"issue":"14","key":"10.1016\/j.lungcan.2023.03.003_b0020","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21144919","article-title":"Irinotecan-Still an Important Player in Cancer Chemotherapy: A Comprehensive Overview","volume":"21","author":"Kciuk","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"12","key":"10.1016\/j.lungcan.2023.03.003_b0025","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1038\/bjc.1998.362","article-title":"Determinants of CPT-11 and SN-38 activities in human lung cancer cells","volume":"77","author":"van Ark-Otte","year":"1998","journal-title":"Br J Cancer"},{"issue":"8","key":"10.1016\/j.lungcan.2023.03.003_b0030","first-page":"2182","article-title":"Clinical pharmacokinetics and metabolism of irinotecan (CPT-11)","volume":"7","author":"Mathijssen","year":"2001","journal-title":"Clin Cancer Res"},{"issue":"6","key":"10.1016\/j.lungcan.2023.03.003_b0035","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1021\/bc0155420","article-title":"Identification and activities of human carboxylesterases for the activation of CPT-11, a clinically approved anticancer drug","volume":"12","author":"Senter","year":"2001","journal-title":"Bioconjug Chem"},{"issue":"Suppl","key":"10.1016\/j.lungcan.2023.03.003_b0040","doi-asserted-by":"crossref","first-page":"S44","DOI":"10.1007\/s002800051078","article-title":"Multiplicity of biliary excretion mechanisms for the camptothecin derivative irinotecan (CPT-11), its metabolite SN-38, and its glucuronide: role of canalicular multispecific organic anion transporter and P-glycoprotein","volume":"42","author":"Sugiyama","year":"1998","journal-title":"Cancer Chemother Pharmacol"},{"issue":"4","key":"10.1016\/j.lungcan.2023.03.003_b0045","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1006\/bbrc.2001.5850","article-title":"Transport of 7-ethyl-10-hydroxycamptothecin (SN-38) by breast cancer resistance protein ABCG2 in human lung cancer cells","volume":"288","author":"Nakatomi","year":"2001","journal-title":"Biochem Biophys Res Commun"},{"issue":"17","key":"10.1016\/j.lungcan.2023.03.003_b0050","doi-asserted-by":"crossref","first-page":"3870","DOI":"10.1158\/1078-0432.CCR-14-3321","article-title":"First-in-Human Trial of a Novel Anti-Trop-2 Antibody-SN-38 Conjugate, Sacituzumab Govitecan, for the Treatment of Diverse Metastatic Solid Tumors","volume":"21","author":"Starodub","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"29","key":"10.1016\/j.lungcan.2023.03.003_b0055","doi-asserted-by":"crossref","first-page":"3338","DOI":"10.1200\/JCO.2017.73.9011","article-title":"Phase I\/II Trial of Labetuzumab Govitecan (Anti-CEACAM5\/SN-38 Antibody-Drug Conjugate) in Patients With Refractory or Relapsing Metastatic Colorectal Cancer","volume":"35","author":"Dotan","year":"2017","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.lungcan.2023.03.003_b0060","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1056\/NEJMoa1914510","article-title":"Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer","volume":"382","author":"Modi","year":"2020","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.lungcan.2023.03.003_b0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2021.100204","article-title":"Sacituzumab govitecan and trastuzumab deruxtecan: two new antibody-drug conjugates in the breast cancer treatment landscape","volume":"6","author":"Adams","year":"2021","journal-title":"ESMO Open"},{"issue":"20","key":"10.1016\/j.lungcan.2023.03.003_b0070","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1101\/gad.196451.112","article-title":"Regulated proteolysis of Trop2 drives epithelial hyperplasia and stem cell self-renewal via beta-catenin signaling","volume":"26","author":"Stoyanova","year":"2012","journal-title":"Genes Dev"},{"key":"10.1016\/j.lungcan.2023.03.003_b0075","doi-asserted-by":"crossref","unstructured":"S. Lenart, P. Lenart, J. Smarda, J. Remsik, K. Soucek, P. Benes, Trop2: Jack of All Trades, Master of None, Cancers (Basel) 12(11) (2020).","DOI":"10.3390\/cancers12113328"},{"issue":"1","key":"10.1016\/j.lungcan.2023.03.003_b0080","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1186\/s12931-016-0463-z","article-title":"Increased expression of TROP2 in airway basal cells potentially contributes to airway remodeling in chronic obstructive pulmonary disease","volume":"17","author":"Liu","year":"2016","journal-title":"Respir Res"},{"issue":"15","key":"10.1016\/j.lungcan.2023.03.003_b0085","doi-asserted-by":"crossref","first-page":"3729","DOI":"10.1158\/1078-0432.CCR-17-1507","article-title":"Nintedanib Is Active in Malignant Pleural Mesothelioma Cell Models and Inhibits Angiogenesis and Tumor Growth In Vivo","volume":"24","author":"Laszlo","year":"2018","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.lungcan.2023.03.003_b0090","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1002\/ijc.2910410210","article-title":"Monoclonal antibodies against mesothelial membrane antigen discriminate between malignant mesothelioma and lung adenocarcinoma","volume":"41","author":"Stahel","year":"1988","journal-title":"Int J Cancer"},{"issue":"16","key":"10.1016\/j.lungcan.2023.03.003_b0095","doi-asserted-by":"crossref","first-page":"3242","DOI":"10.1038\/emboj.2011.257","article-title":"Regulation of TFEB and V-ATPases by mTORC1","volume":"30","author":"Pena-Llopis","year":"2011","journal-title":"EMBO J"},{"issue":"11","key":"10.1016\/j.lungcan.2023.03.003_b0100","doi-asserted-by":"crossref","first-page":"2491","DOI":"10.1021\/bi902135e","article-title":"Structural analysis and functional implications of the negative mTORC1 regulator REDD1","volume":"49","author":"Vega-Rubin-de-Celis","year":"2010","journal-title":"Biochemistry"},{"issue":"2","key":"10.1016\/j.lungcan.2023.03.003_b0105","first-page":"1782","article-title":"TROP2 promotes cell proliferation and migration in osteosarcoma through PI3K\/AKT signaling","volume":"18","author":"Gu","year":"2018","journal-title":"Mol Med Rep"},{"issue":"26","key":"10.1016\/j.lungcan.2023.03.003_b0110","doi-asserted-by":"crossref","first-page":"22496","DOI":"10.18632\/oncotarget.4318","article-title":"Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC)","volume":"6","author":"Goldenberg","year":"2015","journal-title":"Oncotarget"},{"issue":"17","key":"10.1016\/j.lungcan.2023.03.003_b0115","doi-asserted-by":"crossref","first-page":"3717","DOI":"10.1016\/j.febslet.2010.05.021","article-title":"Focus on histone variant H2AX: to be or not to be","volume":"584","author":"Yuan","year":"2010","journal-title":"FEBS Lett"},{"issue":"2","key":"10.1016\/j.lungcan.2023.03.003_b0120","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1097\/00001813-199404000-00011","article-title":"Activity of CPT-11 (irinotecan hydrochloride), a topoisomerase I inhibitor, against human tumor colony-forming units","volume":"5","author":"Shimada","year":"1994","journal-title":"Anticancer Drugs"},{"issue":"3","key":"10.1016\/j.lungcan.2023.03.003_b0125","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.lungcan.2004.12.002","article-title":"Cancer, B Leukemia Group, Irinotecan for malignant mesothelioma A phase II trial by the Cancer and Leukemia Group B","volume":"48","author":"Kindler","year":"2005","journal-title":"Lung Cancer"},{"issue":"11","key":"10.1016\/j.lungcan.2023.03.003_b0130","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1002\/(SICI)1097-0142(19990601)85:11<2375::AID-CNCR12>3.0.CO;2-E","article-title":"Cisplatin in combination with irinotecan in the treatment of patients with malignant pleural mesothelioma: a pilot phase II clinical trial and pharmacokinetic profile","volume":"85","author":"Nakano","year":"1999","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.lungcan.2023.03.003_b0135","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1097\/00001813-200004000-00005","article-title":"Docetaxel and irinotecan (CPT-11) in the treatment of malignant pleural mesothelioma\u2013a feasibility study","volume":"11","author":"Knuuttila","year":"2000","journal-title":"Anticancer Drugs"},{"issue":"2","key":"10.1016\/j.lungcan.2023.03.003_b0140","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1097\/00001813-200002000-00005","article-title":"In vitro sensitivity of normal human mesothelial and malignant mesothelioma cell lines to four new chemotherapeutic agents","volume":"11","author":"Ollikainen","year":"2000","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.lungcan.2023.03.003_b0145","doi-asserted-by":"crossref","first-page":"2789","DOI":"10.2147\/IJN.S158426","article-title":"SN38-loaded <100 nm targeted liposomes for improving poor solubility and minimizing burst release and toxicity: in vitro and in vivo study","volume":"13","author":"Fang","year":"2018","journal-title":"Int J Nanomedicine"},{"issue":"2","key":"10.1016\/j.lungcan.2023.03.003_b0150","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.canlet.2015.02.011","article-title":"Nanoparticle delivery of an SN38 conjugate is more effective than irinotecan in a mouse model of neuroblastoma","volume":"360","author":"Iyer","year":"2015","journal-title":"Cancer Lett"},{"issue":"1","key":"10.1016\/j.lungcan.2023.03.003_b0155","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s12943-020-01305-3","article-title":"Targeting AURKA in Cancer: molecular mechanisms and opportunities for Cancer therapy","volume":"20","author":"Du","year":"2021","journal-title":"Mol Cancer"},{"key":"10.1016\/j.lungcan.2023.03.003_b0160","doi-asserted-by":"crossref","unstructured":"D. Galetta, L. Cortes-Dericks, Promising Therapy in Lung Cancer: Spotlight on Aurora Kinases, Cancers (Basel) 12(11) (2020).","DOI":"10.3390\/cancers12113371"},{"issue":"3","key":"10.1016\/j.lungcan.2023.03.003_b0165","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.lungcan.2010.03.005","article-title":"Antiproliferative effect of Aurora kinase targeting in mesothelioma","volume":"70","author":"Crispi","year":"2010","journal-title":"Lung Cancer"},{"issue":"6","key":"10.1016\/j.lungcan.2023.03.003_b0170","doi-asserted-by":"crossref","first-page":"2970","DOI":"10.1158\/0008-5472.CAN-05-3907","article-title":"Global gene expression profiling of pleural mesotheliomas: overexpression of aurora kinases and P16\/CDKN2A deletion as prognostic factors and critical evaluation of microarray-based prognostic prediction","volume":"66","author":"Lopez-Rios","year":"2006","journal-title":"Cancer Res"},{"key":"10.1016\/j.lungcan.2023.03.003_b0175","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.789244","article-title":"Aurora Kinase A as a Diagnostic and Prognostic Marker of Malignant Mesothelioma","volume":"11","author":"Guo","year":"2021","journal-title":"Front Oncol"},{"issue":"23","key":"10.1016\/j.lungcan.2023.03.003_b0180","doi-asserted-by":"crossref","DOI":"10.3390\/molecules26237294","article-title":"A New Kid on the Block: Sacituzumab Govitecan for the Treatment of Breast Cancer and Other Solid Tumors","volume":"26","author":"Pavone","year":"2021","journal-title":"Molecules"},{"issue":"20","key":"10.1016\/j.lungcan.2023.03.003_b0185","doi-asserted-by":"crossref","DOI":"10.3390\/molecules25204764","article-title":"Antibody-Drug Conjugates for Cancer Therapy","volume":"25","author":"Hafeez","year":"2020","journal-title":"Molecules"}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500223000880?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500223000880?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T13:07:47Z","timestamp":1759237667000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500223000880"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":37,"alternative-id":["S0169500223000880"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2023.03.003","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"TROP2 expression and SN38 antitumor activity in malignant pleural mesothelioma cells provide a rationale for antibody-drug conjugate therapy","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2023.03.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}